CoChat

A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression

Open access
Toniolo, Ricardo Alexandre, Silva, Michelle, Fernandes, Francy de Brito Ferreira, Amaral, José Antonio de Mello Siqueira, Dias, Rodrigo da Silva, Lafer, Beny · 2018 · Journal of Neural Transmission

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Depressive episodes are a major cause of morbidity and dysfunction in individuals suffering from bipolar disorder. Currently available treatments for this condition have limited efficacy and new therapeutic options are needed. Extensive research in the pathophysiology of bipolar disorder points to the existence of mitochondrial and bioenergetic dysfunction. We hypothesized that creatine monohydrate, a nutraceutical that works as a mitochondrial modulator, would be effective as an adjunctive therapy for bipolar depression. We conducted a double-blind trial in which 35 patients with bipolar disorder type I or II in a depressive episode by DSM-IV criteria and in use of regular medication for the treatment of this phase of the disease were randomly allocated into two adjunctive treatment groups for 6 weeks: creatine monohydrate 6 g daily (N = 17) or placebo (N = 18). Primary efficacy was assessed by the change in the Montgomery-Åsberg Depression Rating Scale (MADRS). We did not find a statistically significant difference in the comparison between groups for the change in score on the MADRS after 6 weeks in an intention-to-treat (ITT) analysis (p = 0.560; Cohen's d = 0.231). However, we found significant superiority of creatine add-on vs. placebo when we considered the remission criterion of a MADRS score ≤ 12 at week 6 analyzing the outcome of the 35 randomized patients on ITT (52.9% remission in the creatine group vs. 11.1% remission in the placebo group) and of the 23 completers (66.7% remission in the creatine group vs. 18.2% remission in the placebo group) (p = 0.012; OR = 9.0 and p = 0.036; OR = 9.0, respectively). Two patients who received creatine switched to hypomania/mania early in the trial. No clinically relevant physical side-effects were reported or observed. This proof-of-concept study, aiming to restore brain bioenergetics using an adjunctive mitochondrial modulator, is not conclusive on the efficacy of creatine add-on for bipolar depression, but suggests that this compound may have a role in the adjunctive treatment of this phase of the illness. Further investigation through randomized controlled trials with larger samples should be conducted to verify the efficacy of creatine supplementation for bipolar depression and also for subsyndromal depressive symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00702-017-1817-5

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Screening, randomization and disposition of 35 patients with bipolar depression assigned to adjunctive treatment with creatine monohydrate or placebo
Fig. 1 Screening, randomization and disposition of 35 patients with bipolar depression assigned to adjunctive treatment with creatine monohydrate or placeboCC BY · PubMed Central
Fig. 2 Observed and last observation carried forward Montgomery–Åsberg Depression Rating Scale (MADRS) scores at each treatment week for 27 patients with bipolar depression assigned to a 6-week adjunctive treatment with creatine monohydrate or placebo
Fig. 2 Observed and last observation carried forward Montgomery–Åsberg Depression Rating Scale (MADRS) scores at each treatment week for 27 patients with bipolar depression assigned to a 6-week adjunctive treatment with creatine monohydrate or placeboCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. First MB Spitzer RL Gibbon M Williams Janet BW Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV) 1996 Washington, DC American Psychiatric Press

Cited by

See all 60

Metadata

Authors
Toniolo, R. A., Silva, M., Fernandes, F. D. B. F., Amaral, J. A. D. M. S., Dias, R. D. S., & Lafer, B.
Affiliations
Universidade de São Paulo (BR)
Corresponding author
Toniolo, Ricardo Alexandre
Venue
Journal of Neural Transmission
Published
2017-11-24
Volume
125
Issue
2
Pages
247-257
ISSN
  • 0300-9564 (ISSN-L)
  • 1435-1463
OpenAlex
W2770274569
Cited by
50
References
55
Citations by year
2026: 10 · 2025: 9 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 4
FWCI
2.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neural Transmission (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Brain and Behavior Research Foundation (20202)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
creatine monohydrate, bipolar depression, bipolar disorder, adjunctive therapy, mitochondrial dysfunction, brain bioenergetics, nutraceuticals, depression remission, Montgomery-Asberg Depression Rating Scale, subsyndromal depressive symptoms, placebo comparison, mood stabilizers
MeSH terms
Proof of Concept Study, Adult, Antidepressive Agents, Antioxidants, Bipolar Disorder, Creatine, Double-Blind Method, Humans, Middle Aged, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression. https://app.cochat.ai/papers/10.1007/s00702-017-1817-5
The paper
Toniolo, R. A., Silva, M., Fernandes, F. D. B. F., Amaral, J. A. D. M. S., Dias, R. D. S., & Lafer, B. (2018). A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression. Journal of Neural Transmission. https://doi.org/10.1007/s00702-017-1817-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.